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Nonalcoholic fatty liver disease encompasses a spectrum 
of pathology ranging from simple steatosis to nonalcoholic 
steatohepatitis (NASH) and cirrhosis, but the mechanisms 
and mediators that regulate necroinflammation and dis-
ease progression are still poorly understood (1–3). NASH-
associated hepatic fibrosis is currently the target of 
significant scientific and clinical interest, in particular, the 
mechanisms  regulating activation of hepatic  stellate  cells 
(HSCs), which are the major fibrogenic effectors (1–3). 
Quiescent HSCs contain abundant complex lipids that are 




duction of extracellular matrix, including I(I) collagen.
Among the most abundant proteins on LDs are mem-
bers of the perilipin (Plin) family of lipid droplet proteins, 
some of which (e.g., Plin2) play important roles in the reg-
ulation of lipid metabolism in a variety of tissues including 
liver (4–7). Our previous observations demonstrated that 
Abstract Hepatic stellate cell (HSC) activation occurs along 
with decreased Perilipin5 (Plin5) and liver fatty acid-binding 
protein (L-Fabp) expression and coincident lipid droplet 
(LD) depletion. Conversely, the activated phenotype is re-
versible in WT HSCs upon forced expression of Plin5. Here, 
we asked if L-Fabp expression is required for Plin5-mediated 
rescue of the quiescent phenotype. Lentiviral Plin5 trans-
duction of passaged L-Fabp/ HSCs failed to reverse activa-
tion markers or restore lipogenic gene expression and LD 
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ral Plin5 transduced L-Fabp/ HSCs restored both the qui-
escent phenotype and LD formation, an effect also mediated 
by adenoviral intestine-Fabp or adipocyte-Fabp. Expression 
of exogenous Plin5 in activated WT HSCs induced a tran-
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a broader role for this LD protein in the regulation of he-
patic fibrogenesis (9). In keeping with this suggestion, we 
recently reported that exogenous Plin5 significantly in-
creased intracellular lipid content and restored LDs in 





may promote a quiescent state (10, 11) and could be a 
functional strategy for inhibiting fibrogenesis (10, 11).
Other players involved in HSC lipid metabolism include 
members of the fatty acid-binding protein (FABP) family of 
lipid-binding proteins, which are  involved  in  the uptake, 
transport,  and  metabolism  of  FAs,  retinoids,  and  other 
lipid ligands (12). Among these FABPs, liver Fabp (L-Fabp, 
Fabp1)  is  abundantly  expressed  in both hepatocytes  and 
enterocytes  and plays  a  key  role  in  high-fat  diet-induced 
hepatic steatosis (13–17) and also in the development and 
progression of diet-induced NASH in vivo (18). L-Fabp is 
also abundantly expressed in quiescent HSCs, and our pre-




Here, we sought to expand understanding of the path-
ways that regulate HSC activation and LD turnover in rela-










followed guidelines issued by the National Institutes of Health. 
Congenic L-Fabp knockout mice (L-Fabp/) were generated and 
maintained  as  described  previously  (18). WT male  and  female 
C57BL/6J  mice  were  purchased  from  Jackson  Laboratory,  Bar 
Harbor, MA, and were housed  in a  temperature-controlled ani-
mal facility (23°C) with a 12:12 h light-dark cycle and allowed free 
access  to  regular  chow  and  water.  Male  and  female  WT  and 
L-Fabp/ mice were maintained on a standard rodent chow diet 
(PicoLab Rodent Diet 20) and mice of comparable ages (12–16 
weeks) were used for isolation of HSCs for experiments.
Isolation and culture of HSCs
HSCs were isolated by pronase-collagenase perfusion in situ be-
fore density gradient centrifugation, as previously described (19). 
Freshly  isolated  HSCs  were  cultured  in  DMEM  supplemented 
with 20% FBS. Cells were passaged in DMEM with 10% FBS. Un-
less otherwise  indicated, semi-confluent HSCs with four to nine 
passages were used in all experiments. In some experiments, len-
tivirus transduced HSCs were treated with L-Fabp inhibitors (sup-
plemental  Fig.  S1),  at  the  indicated  doses  for  24  h.  All  FABP 
inhibitors were synthesized by a commercial vendor on a contract 
basis (Nanosyn, Santa Clara, CA). Compound purity was deter-
mined by LC-MS, and was >98% for all compounds. The design of 
these  inhibitors was based on structural  similarity  to 8-anilinon-
aphthalene-1-sulfonic acid (1, 8 ANS), which contains both a sul-
fonic acid and an amine group and competes for binding within 
the  ligand  binding  pocket  of  hydrophobic  ligand  binding  pro-
teins as determined using a displacement assay as previously de-
scribed  (20).  Purified  recombinant  FABP  from  liver,  intestine, 
epithelium, heart, and adipose were used to evaluate compound 





to determine an IC50  for  each  compound  to  displace  1,8-ANS 
from the ligand-binding pocket of each FABP isoform. Oleic acid 











ies reported. Where indicated, the AMPK inhibitor Compound C 
(Sigma, St Louis, MO) was added as indicated in the Fig. 6 legend 
at a dose of 20 µM (8).
RNA extraction and real-time PCR
Total RNA was extracted from cells by TRI-Reagent, following 
the protocol recommended by the manufacturer (Sigma). Total 
RNA was  treated with DNase  I  before  the  synthesis  of  the  first 
strand of cDNA. Real-time PCR was performed as previously de-
scribed using SYBR Green Supermix (21). mRNA levels were ex-









Recombinant expression constructs, antisera, and 
immunoblots
Construction  of  the  recombinant  lentiviral  (LV)-Plin5-yellow 
fluorescent protein (YFP) and the control LV-YFP were as previ-





the N terminus and cloned into the pVQ AdCMV shuttle plasmid 
for recombination, amplification, and purification (ViraQuest 
Labs). Ad-A-Fabp was generated as previously described (23). In 
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VA) to allow packaging and amplification. Large scale adenovirus 
preparations were obtained from 10 cm plates in which the media 
was collected, centrifuged at 20,000 g for 10 min to pellet the cel-
lular debris, and the supernatant containing virus particles recov-
ered and frozen in aliquots at 70°C.  Antisera  to  FABPs  and 
perilipins  were  previously  described  (16).  Western  blotting 
analyses were  conducted  as we previously  described  (8). Thirty 
micrograms of proteins per well were used in all immunoblots, 
except where indicated as in Fig. 1.
Knockdown of perilipin 2 by shRNA
The RNAi sequences targeting mouse Plin2 mRNA was selected 
using online RNAi design program  from Thermo Fisher Scien-




Plin2  shRNA  was  used  as  a  negative  control.  Construction  of 
shRNA expression cassettes and subsequent cloning in the lenti-
viral  vector  pFLRu were  conducted  as we  previously  described 
(24).
Plasmids, transient transfection, and luciferase activity 
assays
The  luciferase  reporter  plasmid  pPPRE-Luc  contains  three 








In situ quantification of LDs and lipid assays
Oil Red O staining was undertaken on HSCs seeded on auto-
claved cover  slips  in a 6-well plate and cultured  in DMEM with 





(18).  Cells  of  interest  were  digitized  and  circled  individually 
within the image and the numbers of LDs per cell automatically 
calculated.  Positive  staining  was  adjusted  by  subtracting  back-
ground control signals. The results were collected and expressed 
as a mean number of LDs per cell based on at least 10 cells. Intra-
cellular FFAs and triglycerides (TG) were colorimetrically deter-
mined using kits  from BioVision,  Inc.  (Mountain View, CA), 
following the manufacturer’s protocol (29).
Fatty acid uptake and lipolysis assays
WT-passaged HSCs were transduced with or without LV-Plin5-
YFP, or LV-YFP, or LV-Plin5-YFP plus Ad-L-Fabp. Cells were incu-
bated  in  media  containing  2µCi  [3H]oleic  acid  (ART  0198, 
American Radiolabeled Chemicals, St. Louis, MO) and 250 µM 
oleic  acid  albumin  (O-3008,  Sigma-Aldrich)  for 4 h  at  37°C, 
washed,  and  extracted  with  chloroform-methanol  as  described 
(15). Radiolabeled lipids were separated by thin layer chromatog-
raphy, and the position of 3H-lipids was determined by migration 
of unlabeled standards. Assays were performed in triplicate, and 
normalized to cellular protein content.
For  lipolysis  assays,  cells  (groups  as  described  above)  were 
collected in PBS and frozen. Cell pellets were homogenized in 
0.25M sucrose, 1 mM EDTA, 1 mM DTT, with protease inhibi-




BSA  for  1  h  at  37°C.  Assays  were  stopped  by  the  addition  of 
chloroform-methanol,  extracted,  and  analyzed  by  thin  layer 
chromatography as described above, and regions comigrating 
with unlabeled oleate were scraped and counted. Data were cor-
rected for nonspecific hydrolysis and normalized to cellular 
protein.
Analysis of cellular retinol and retinyl esters
WT-passaged HSCs were transduced with or without LV-Plin5-
YFP, or LV-YFP, or LV-Plin5-YFP plus Ad-L-Fabp. HSC concentra-






treated with  an  equal  volume of  absolute  ethanol  containing  a 
known amount of retinyl acetate as an internal standard. The reti-






mm Ultrasphere  C18  column  (Beckmann,  Fullerton,  CA)  pre-
ceded by a C18 guard column (Supelco, Bellefonte, PA) using 
70% acetonitrile-15% methanol-15% methylene chloride as  the 
running  solvent  flowing  at  1.8 ml/min.  Retinol  and  individual 
retinyl esters (retinyl palmitate, oleate, linoleate, and stearate) 
were detected at 325 nm and identified by comparing the reten-
tion times and spectral data of experimental compounds with 
those of authentic standards. Concentrations of retinol and reti-
nyl esters in the HSCs were quantitated by comparing integrated 
peak areas of each retinoid against  those of known amounts of 
purified standards. Loss during extraction was accounted for by 
adjusting for the recovery of internal standard added immediately 
after homogenization of the samples.
Statistical analyses
Differences between means were evaluated using an unpaired 
two-sided  Student’s  t-test  (P < 0.05 considered as significant). 
Where appropriate, comparisons of multiple treatment condi-
tions with controls were analyzed by ANOVA with the Dunnett’s 
test for post hoc analysis.
RESULTS
L-Fabp is critical for Plin5-mediated rescue of LD 
formation in HSCs
To determine the role of L-Fabp in Plin5-mediated res-
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failed to restore LD formation in HSCs from L-Fabp/mice 
(Fig. 1A).
We found that Plin5 was expressed in both freshly iso-
lated WT and L-Fabp/ HSCs (Fig. 1B, C), although the 
abundance of Plin5 mRNA was lower in L-Fabp/ (Ct value 
≈28.5) compared with WT HSCs (Ct value ≈28.1) (Day 1) 
(Fig. 1B). These findings  led us  to ask whether germline 








in a comparable increase in (exogenous) Plin5 expression 
in both passaged-WT and L-Fabp/ HSCs (Fig. 1D). Con-
sidered together, these findings reveal expression of Plin5 
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in HSCs. We found that forced expression of exogenous 
Plin5 in both WT and L-Fabp/ HSCs induced expression of 
Plin2 (Fig. 1E), but that the expression of other lipid drop-
let  protein  genes,  including  Plin3  and  hypoxia-induced 
gene 2 (HIG2), were unaffected. We further examined the 







missive role, along with Plin5,  in  increasing cellular  lipid 
content  and  restoring  LD  formation  in WT HSCs. How-
ever, for reasons explored below, and despite comparable 
expression  of  exogenous  Plin5  following  lentiviral  trans-
duction, this response fails to occur in L-Fabp/ HSCs.
L-Fabp is required for Plin5-mediated reversal of HSC 







we examined LXR and PPAR induction as models of pro-
lipogenic  induction  (32–34)  and  also Wnt/-catenin  sig-
naling which, via cross-talk with PPAR, interferes with its 
functions and is considered antilipogenic (35, 36). We 
transduced WT  or L-Fabp/  HSCs  with  LV-Plin5-YFP  or 
LV-YFP and after selection, transfected those cells with lu-
ciferase  reporter  plasmids  LXR-Luc,  PPRE-Luc,  or  TOP-
Flash (see details in Methods). As shown in Fig. 2A, elevated 
luciferase  activity  was  found  in  LXR-Luc  and  PPRE-Luc-
transfected WT but  not L-Fabp/ HSCs transduced with 
Plin5. Conversely, we observed reduced luciferase activity 
in WT but not L-Fabp/ HSCs transfected with TOPFlash-
Luc and transduced with Plin5.
























Introduction of L-Fabp into L-Fabp/ HSCs rescues 
Plin5-mediated reversal of activation and prolipogenic 
activity
We introduced Ad L-Fabp (or LacZ control virus) into 





in both genotypes (Fig. 3A). Real-time PCR analyses indi-
cated that forced expression of L-Fabp induced expression 
of Plin5  in both passaged WT HSCs and L-Fabp/ HSCs 
(Fig. 3B) as previously reported (18). As shown in Fig. 3C, 
upon rescue of L-Fabp expression in L-Fabp/ HSCs, Plin5 
transduction decreased expression of -SMA  and  I(I) 
procollagen mRNAs and also increased mRNA abundance 
of SREBP-1 and PPAR (Fig. 3C). Forced L-Fabp expres-
sion  also  restored  cellular  FFA  and TG  content  in  Plin5 
transduced L-Fabp/ HSCs (Fig. 3D).
As noted  above  (Fig.  1A),  Plin5  transduction  into WT 
HSCs led to increased mRNA expression of Plin2. In view 
of prior studies demonstrating a role of Plin2 in LD forma-
tion in HSCs (40), we sought to clarify the role of Plin2 in 
the coordinated interactions of L-Fabp and Plin5 in LD for-




We confirmed that exogenous Plin5 increased endogenous 
Plin2 protein expression in L-Fabp/ HSCs, but Ad-L-Fabp 
rescue caused no further upregulation of Plin2 expression 
(Fig. 3E). Furthermore, Oil Red O staining revealed that 
shRNA inhibition of Plin2 had no effect on LD formation 
in L-Fabp/ HSCs  transduced with Plin5  and Ad L-Fabp 
(Fig. 3E). Finally, to examine the role of L-Fabp and Plin5 
in  coordinating  transcriptional  activation  of  lipogenic 
pathways, Ad-L-Fabp infected, Plin5 transduced L-Fabp/ 
HSCs  were  transiently  transfected  with  LXR-Luc,  PPRE-
Luc, or TOPFlash plasmids as above. Luciferase activity assays 
revealed  that  Ad-L-Fabp  rescued  Plin5-mediated  tran-
scriptional induction in L-Fabp/ HSCs transfected with 
LXR-Luc or PPRE-Luc, and, conversely, reduced luciferase 
activities  in  L-Fabp/  HSCs  transfected  with  TOPFlash 
(Fig. 3F). These results collectively reinforce the conclu-
sions  that  expression  of  exogenous  L-Fabp  in  L-Fabp/ 
HSCs rescues the ability of Plin5 to reverse HSC activation, 
elevate cellular lipid content, and regulate prolipogenic 
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Expression of other FABPs in L-Fabp/ HSCs rescues the 
ability of Plin5 to restore LD formation
Consistent with  the findings  above,  lentiviral Plin5  re-
stored LD  formation  in WT HSCs with Ad-LacZ or with 
Ad-L-Fabp,  suggesting  that  endogenous  expression  of  
L-Fabp is sufficient for these effects in WT HSCs. However, 
LDs  were  only  restored  in  lentivirally  transduced  Plin5 
L-Fabp/ HSCs transfected with Ad-L-Fabp, but not with 
Ad-LacZ  (the  lower  right  panel  with  arrow  of  the  lower 









together with Plin5 restored LDs in L-Fabp/ HSCs (pan-
els with arrows in Fig. 4C). In addition, and as found with 
the Ad-L-Fabp transduction experiments reported above, 
neither  Ad-I-Fabp  or  Ad-A-Fabp  transduction  alone  in 
L-Fabp/ HSCs restored LD formation (Fig. 4 C). These 
findings again point  to a role  for endogenous L-Fabp in 
LD  formation  in  response  to  Plin5  transduction  in WT 
HSCs. Although we did not systematically examine the 
entire range of FABPs, our results suggest that the expres-
sion of exogenous L-Fabp as well as other FABPs effectively 
rescues the ability of Plin5 to restore LD formation in 
L-Fabp/ HSCs.
Small molecule inhibitors of L-Fabp impair the ability of 
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with  varying  degrees  of  specificity  and  potency  (supple-
mental Fig. S1).
We  focused  on  the  most  selective  L-Fabp  inhibitor 
(NSOP00313, abbreviated as NSOP313) at increasing doses 
in WT HSCs  for 24 h before and after  transduction with 
LV-Plin5-YFP. We  found  that  treatment with NSOP313 
caused a dose-dependent decrease in the formation of LDs 
(Fig.  5C),  along  with  decreased  cellular  FFA  and  TG  
content  (Fig.  5E).  Moreover,  higher  doses  of  NSOP313 
triggered  upregulation  of mRNAs  associated  with HSC 
activation and decreased expression of PPAR mRNA (Fig. 
5D).








ing cellular lipid content, and restoring LD formation in 
HSCs.























Supplemental Material can be found at:
Plin5 regulates lipid droplet formation via L-Fabp 423
AMPK activation is required for L-Fabp-mediated  
Plin5-dependent restoration of lipogenesis and  
quiescence in L-Fabp/ HSCs
We previously reported that exogenous Plin5 stimulated 
AMPK activation in WT HSCs, which in turn induced the 




L-Fabp  in  the  activation  of  AMPK  by  Plin5  in  L-Fabp/ 
HSCs. As shown in Fig. 6A, forced expression of exogenous 
Plin5 increased the abundance of phosphorylated AMPK 
in  both  WT  and  L-Fabp/ HSCs. By contrast, forced 





We further studied L-Fabp/  HSCs  transduced  with  LV-
Plin5-YFP or LV-YFP and subsequent Ad-L-Fabp rescue, fol-
lowed  by  treatment  with  the  selective  AMPK  inhibitor 
Compound C at 20 M for 24 h. AMPK inhibition signifi-
cantly attenuated the effects of Plin5 and L-Fabp on regu-
lating  expression  of  genes  relevant  to  HSC  activation, 
lipogenesis, and lipolysis in L-Fabp/ HSCs (Fig. 6B) and 





AMPK  inhibition  also  reversed  the  transcriptional  pro-
grams of  lipogenic  induction of LXR and PPAR and of 
Wnt suppression as indicated by the luciferase assays using 
reporter  constructs  outlined  above  (Fig.  6E).  Taken  to-
gether, these results strongly suggest that AMPK activation 
is  required  for  the  coordination  of  L-Fabp with  Plin5  in 
mediating rescue of quiescence in L-Fabp/ HSCs.
DISCUSSION
We  recently  reported  that  the  activation  of  HSCs  was 
temporally coincident with the loss of LDs, the depletion of 
Plin5 (8), and the suppression of L-Fabp expression (18) 
both in vitro and in vivo. The current findings extend those 
observations  by  demonstrating  that  exogenous  Plin5  in-
duces endogenous L-Fabp expression in WT HSCs, suggest-
ing a requirement for L-Fabp in the rescue of quiescence 
mediated by Plin5. We further show that either lifelong 
absence of L-Fabp (in L-Fabp/ HSCs) or pharmacologic 
inhibition  of  endogenous  L-Fabp  in  WT  HSCs  abro-
gated the ability of Plin5 to reverse HSC activation and also 
eliminated LD formation and lipid accumulation. Con-
versely,  adenoviral-mediated  expression  of  exogenous  
L-Fabp  in L-Fabp/ HSCs rescued the ability of Plin5 to 
restore quiescence. Accordingly, a central conclusion of 
this work is that L-Fabp is required for Plin5-mediated res-
cue of cellular quiescence in HSCs, through pathways that 
intersect with the induction of lipogenic gene programs. 
That being said, we recognize that the range of functions of 
Plin5 implied from studies in animal models is still contro-
versial (9, 41).
Accumulating  evidence  has  shown  the  importance  of 
cellular lipids in maintaining HSCs in a state of quiescence, 
although the precise roles of key LD proteins remain elu-
sive.  At  the  molecular  level,  independent  work  strongly 






metabolic roles to Plin5 and demonstrated interactions 
with other proteins that are requisite for these functions 
(41). Our  results  support  an  important  role  for Plin5  in  
elevating cellular lipid content in HSCs (8); namely, induc-
tion of  lipogenic pathways through transcriptional activa-
tion  of  SREBP  and  PPAR dependent pathways. We 
recognize that further studies will be required to explore 
the precise mechanisms of increased de novo lipogenesis 
observed.
Studies  suggest  that  lecithin-retinol  acyltransferase 
(LRAT) acts as the sole retinol acyltransferase in the liver 
and is responsible for the formation of retinyl esters in 
HSCs (46). LRAT  is highly expressed  in quiescent HSCs 
and downregulated during HSC activation (47). Lrat / 
Fig. 4.  Expression of other FABPs in L-Fabp/HSCs 
rescues the ability of Plin5 to restore LD formation. 
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mice showed a striking total absence of large lipid-containing  
droplets that normally store hepatic retinoid within HSCs 
(48). However,  the  absence of  retinyl  ester-containing  
LDs does not promote either spontaneous HSC activa-
tion, or worsen bile duct ligation-induced or carbon tetra-
chloride-induced  liver  fibrosis  (47).  Our  earlier  studies 
showed that exogenous Plin5 had no impact on the ex-
pression of endogenous LRAT in WT HSCs (8). We con-
sidered the possibility that Plin5 and L-Fabp transduction 
might modify retinol content of HSCs but our findings 
demonstrated only very low levels of retinol with no dif-
ferences by genotype and retinyl esters were undetect-
able (supplemental Table S1). Because these studies were 
undertaken  in  passaged HSCs,  those  findings  would  be 
predicted.
Our findings also highlight a potential functional redun-
dancy  in  the FABP requirement  for Plin5-dependent res-
cue of quiescence and LD formation. We have previously 
shown  that  among  all  FABPs,  L-Fabp  is  by  far  the most 
abundantly expressed member in quiescent HSCs (18). 
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it is tempting to speculate that under circumstances where 
other FABPs might be induced (not examined here), there 
may yet be L-Fabp-independent pathways of restoring qui-
escence. Along these lines, whereas we found that the 
most specific and potent small molecule L-Fabp inhibitor 
(NSOP313) effectively replicated the phenotypes observed 
with L-Fabp  deletion  (Fig.  5),  we  also  found  that  other  
L-Fabp inhibitors (supplemental Fig. S1) showed similar ef-
fects but were either less selective or more toxic.
Our  earlier  work  suggested  that  germline L-Fabp dele-
tion  functions  to  attenuate  high-fat,  fibrogenic,  diet- 
induced hepatic steatosis and fibrosis, raising the possibility 
that  inhibition  of  L-Fabp might  be  a  feasible  strategy  to 
mitigate the effects of hepatic steatosis and necroinflam-
matory  disease  progression.  However,  it  bears  emphasis 
that L-Fabp is abundantly expressed in hepatocytes as well 
as in HSCs and it is possible that its roles and functions are 
exerted in a distinct cell- and metabolic-state-specific con-
text.  The  current  findings  support  the  concept  of  this 
cell-type-specific  function  by  demonstrating  that  genetic 
deletion or pharmacologic inhibition of L-Fabp essentially 




tion of a lipogenic program, might simultaneously induce 
HSC activation.
An  overarching  question  in  our  approach  relates  to 
whether  the expression  levels of exogenous Plin5 are  re-
flective of those encountered physiologically. We demon-
strated that Plin5 protein is indeed detectable in freshly 
isolated HSCs, albeit at levels somewhat lower than those 
seen  with  forced  lentiviral  expression  in  passaged  HSCs 
(Fig. 1C, D). In addition, we previously reported that trans-
duction  of  WT HSCs  with  LV-Plin5-YFP  or  the  empty 
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in HSCs. Additionally, we showed that the major functional 
domain of Plin5 for the LD formation in HSCs resided in 
a domain spanning amino acids 1–188 (aa1–188) of Plin5 
(8)  and  that  overexpression  of  a  subdomain  of  Plin5 
(aa189–463) had no function in LD formation. These prior 
results, coupled with the new findings shown in Fig. 1C and 
D, greatly diminish the possibility of a neomorphic pheno-
type of Plin5  transduction or of  an artifact derived  from 
nonspecific recombinant lentiviral transduction.
It was reported that introduction of Plin2 promotes 




tion  of  the  Plin2  expression  by  Plin2  shRNA  showed no 
impact on the Plin5 function in restoring LD in HSCs (Fig. 
3E). Our  results  and  others  suggest  that  Plin5,  Plin2,  or 




been proposed as the PKA phosphorylation site (50). Phos-
phorylation of Plin5 by PKA stimulated the interaction of 
Plin5 and ATGL (51), which might play a critical role  in 
Plin5-regulated lipolysis (50). Plin5 has been proposed to 
be  an  important molecular  link  that  couples  the  coordi-
nated catecholamine activation of the PKA pathway and of 
lipid droplet lipolysis with transcriptional regulation to 
promote efficient fatty acid catabolism (49). The possibility 
that Plin5 modulates lipid hydrolysis in HSCs and the role, 
if any, for L-Fabp will require further study.
AMPK  is  a well-conserved  serine/threonine-protein  ki-
nase, which acts as a cellular energy and nutrient sensor 
and plays a crucial role in regulation of metabolic pathways 
and cellular energy homeostasis (52). Phosphorylation of 
AMPK at Thr-172 stimulates its kinase activity (53). AMPK 
acts as an anti-lipolytic factor by phosphorylating and in-
activating  hormone-sensitive  lipase  (54)  and  blocking  its 
translocation to LDs (55). We previously showed that the 
activation of AMPK increased cellular TG in HSCs and in-














(i.e., Plin5 →  AMPK  activation →  L-Fabp;  not Plin5 →  
L-Fabp → AMPK activation). This suggestion is supported 










vations  (18).  However,  forced  expression  of  exogenous  
L-Fabp itself did not inhibit expression of HSC activation-
relevant  genes  (Fig.  3C),  augment  cellular  lipid  content 
(Fig. 3D), nor rescue LD formation in L-Fabp/ HSCs (Fig. 
4A).  These  observations  imply  that  despite  the  ability  of 
forced  L-Fabp  expression  to  increase  endogenous  Plin5 
mRNA by 2-  to 3-fold,  the  levels of Plin5 protein  remain 
Fig. 7.  Summary overview of the proposed pathways explored in 
this  report.  Stellate  cell  (HSC)  activation  is  temporally  accompa-
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is  proposed  to  address  the  role  of AMPK  and L-Fabp  in 
mediating/coordinating  the  effects  of  Plin5  in  restoring 
HSC quiescence (Fig. 7). It bears emphasis that this model 
does  not  exclude  other  pathways  by  which  L-Fabp  func-
tions in coordinating with Plin5 the inhibition of HSC acti-
vation.  In  summary, our  results demonstrate  that L-Fabp 
plays a critical role in coordinating with Plin5 in modulat-
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